A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Inherited cardiac ion channelopathies present variable disease severity and sudden cardiac death (SCD) risk.
• Sodium channelopathies, like those caused by SCN5A mutations, are a significant concern.

Purpose of the Study:

• To investigate the modulatory role of cardiac hypertrophy on arrhythmia and SCD risk in individuals with sodium channelopathy.
• To explore the impact of co-morbidities on treatment efficacy in SCN5A mutation carriers.

Main Methods:

• Follow-up data analysis of 164 SCN5A-1795insD mutation-positive individuals and 247 controls.
• Induction of cardiac hypertrophy in mice carrying a homologous mutation (Scn5a1798insD/+) to assess SCD and conduction disturbances.
• Genetic and pharmacological interventions to block pro-hypertrophic response and late sodium current.

Main Results:

• Cardiac hypertrophy and hypertension were associated with increased life-threatening ventricular arrhythmias and SCD in mutation-positive patients over 40.
• Pacemaker implantation was protective against bradycardia-related SCD but less effective for arrhythmias in older patients with hypertrophy.
• Hypertrophy induction in mice with the homologous mutation led to SCD and conduction abnormalities, confirming hypertrophy's modulatory role.
• Genetic and pharmacological interventions targeting hypertrophy and late sodium current mitigated adverse effects.

Conclusions:

• This study demonstrates the first evidence of cardiac hypertrophy modulating arrhythmia risk and treatment effectiveness in inherited sodium channelopathy.
• Rigorous assessment and management of cardiac hypertrophy are essential in SCN5A mutation-positive individuals to improve outcomes.
• Targeting hypertrophy and late sodium current may offer novel therapeutic strategies for managing these patients.